Jennison Associates
IDIX

Jennison Associates’s IDENIX PHARMACEUTICALS INC IDIX Stock Holding History

Jennison Associates’s Portfolio IDIX Stock Details IDIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-735,742
Closed -$3.83M – 753
2013
Q3 		$3.83M Hold
735,742
– – ﹤0.01% 519
2013
Q2 		$2.66M Buy
+735,742
New +$3.01M ﹤0.01% 521

Other funds holding IDIX

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return

Jennison Associates's IDIX Position: Q4 2013 in Review

Jennison Associates sold out of IDENIX PHARMACEUTICALS INC (IDIX) in Q4 2013, closing a stake of 735,742 shares — an estimated $3.83M sold.

Jennison Associates first reported a position in IDIX in Q2 2013 and held it in 2 quarters. The position peaked at $3.83M in Q3 2013. 88 funds tracked by Wall St. Rank hold IDIX as of Q4 2013.

  • Jennison Associates reported no remaining IDENIX PHARMACEUTICALS INC position as of Q4 2013 after selling out during the quarter.
  • Jennison Associates sold 735,742 IDENIX PHARMACEUTICALS INC shares in Q4 2013, an estimated $3.83M.
  • Jennison Associates first reported a position in IDENIX PHARMACEUTICALS INC in Q2 2013 and held it in 2 quarters.
  • Jennison Associates's IDENIX PHARMACEUTICALS INC position peaked at $3.83M in Q3 2013.
  • 88 funds tracked by Wall St. Rank held IDENIX PHARMACEUTICALS INC as of Q4 2013.

Based on Jennison Associates's 13F filing for Q4 2013, filed 10 Feb 2014.